GENFLOW BIOSCIENCES PLC financials
GENFLOW BIOSCIENCES PLC
213800HVOFXRXVEGDN62 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Gross profit | £585.6K | £320.5K |
| Administrative expenses | £2.0M | £1.9M |
| Operating profit (EBIT) | -£1.4M | -£1.6M |
| Net finance income / (cost) | £0 | £0 |
| Profit before tax | -£1.4M | -£1.6M |
| Income tax expense | £0 | £0 |
| Profit for the year | -£1.4M | -£1.6M |
| — attributable to owners | -£1.4M | -£1.6M |
| Total comprehensive income | -£1.5M | -£1.6M |
| Per share | ||
| Basic EPS | £-0.33 | £-0.47 |
| Cash flow statement | ||
| Net cash from operating activities | -£1.4M | -£1.1M |
| Net cash from investing activities | £0 | £0 |
| Net cash from financing activities | £1.3M | £656.6K |
| Net change in cash | -£127.9K | -£425.6K |
| Balance sheet | ||
| Total assets | £452.4K | £385.9K |
| Non-current assets | £1.1K | £2.1K |
| Property, plant & equipment | £1.1K | £2.1K |
| Current assets | £451.3K | £383.8K |
| Trade & other receivables | £339.5K | £105.2K |
| Cash & equivalents | £111.8K | £278.7K |
| Total equity | -£550.8K | -£403.0K |
| Trade & other payables | £1.0M | £788.9K |
| Derived metrics | ||
| Return on equity | 257.4% | 393.8% |
| Cash conversion ratio | 1.01× | 0.68× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade and Other Receivables | -£234.4K | £264.5K |
| Adjustments For Depreciation and Amortisation Expense | £1.1K | £1.2K |
| Adjustments For Increase Decrease In Trade and Other Payables | £214.3K | £239.3K |
| Adjustments For Sharebased Payments | £0 | £0 |
| Cash Advances and Loans From Related Parties | £0 | £0 |
| Comprehensive Income Attributable To Owners of Parent | -£1.5M | -£1.6M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£39.0K | £20.3K |
| Gains Losses On Exchange Differences On Translation Before Tax | -£38.9K | £20.9K |
| Increase Decrease Through Exercise of Warrants Equity | — | £7.0K |
| Increase Decrease Through Transactions With Owners | £1.3M | £663.6K |
| Investments In Subsidiaries | £0 | £0 |
| Issue of Equity | £1.4M | £715.0K |
| Issued Capital | £148.1K | £104.9K |
| Liabilities | £1.0M | £788.9K |
| Net Assets Liabilities | -£550.8K | -£403.0K |
| Other Operating Income Expense | £585.6K | £320.5K |
| Other Reserves | £213.9K | £252.8K |
| Proceeds From Issue of Ordinary Shares | £1.3M | £656.6K |
| Profit Loss From Continuing Operations | -£1.4M | -£1.6M |
| Retained Earnings | -£7.0M | -£5.6M |
| Share Issue Related Cost | £65.4K | £58.4K |
| Share Premium | £6.1M | £4.8M |
Every line item above is a fact tagged in GENFLOW BIOSCIENCES PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.